Anti-PGL-1 antibody levels in Thai leprosy patients

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 27, Issue 4, 1996, Pages 728-733

  Kampirapap, Kowit ^a   Singtham, Namthip ^a  

^a Raj Pracha Samasai Inst   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; GLYCOLIPID; IMMUNOGLOBULIN M; PHENOLIC GLYCOLIPID I, MYCOBACTERIUM LEPRAE;

AGGLUTINATION TEST; ARTICLE; HUMAN; IMMUNOLOGY; LEPROSY; MYCOBACTERIUM LEPRAE; THAILAND;

AGGLUTINATION TESTS; ANTIGENS, BACTERIAL; GLYCOLIPIDS; HUMANS; IMMUNOGLOBULIN M; LEPROSY; MYCOBACTERIUM LEPRAE; THAILAND;

EID: 0030309676     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Becx-Bleumink M. Relapses among leprosy patients treated with multidrug therapy: Experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; Practical difficulties with diagnosing relapses, operational procedures and criteria for diagnosing relapses. Int J Lepr 1992; 60 : 421-35.
2. Becx-Bleumink M. Experience with WHO Recommended Multidrug Therapy (MDT) for Multibacillary (MB) Leprosy patients in the Leprosy Control Program of the All Africa Leprosy and Rehabilitation Training Center In Ethiopia: Appraisal of the recommended duration of MDT for MB patients. Int J Lepr 1991; 59 : 558-67.
3. Boerrigter G, Ponnighaus JM, Fine PEM, Wilson RJ. Four-year follow-up results of a WHO recommended multiple-drug regimen in paucibacillary leprosy patients in Malawi. Int J Lepr 1991; 59 : 225-61.
4. Brennan PJ. Lipid and carbohydrate antigens of M. leprae. Lepr Rev 1986; 57 (suppl 2) : 39-42.
5. Brennan PJ, Barrow WW. Evidence for species-specific lipid antigen in Mycobacterium leprae. Int J Lepr 1980; 48 : 382-7.
6. Britton WJ, Garsia RJ, Basten A. The serological response to the phenolic glycolipid of Mycobacterium leprae in Australian and Nepali leprosy patients. Aust N Z J Med 1987; 17 : 568-73.
7. Buchanan TM, Dissanayake S, Young DB, et al. Evaluation of the significance of antibodies to the phenolic glycolipid of Mycobacterium leprae in leprosy patients and their contacts. Int J Lepr 1983; 51 : 658-9.
8. Chanteau S, Cartel JL, Celerier P, Plichart R, Desforges S, Roux J. PGL-1 antigen and antibody detection in leprosy patients: evolution under chemotherapy. Int J Lepr 1989; 57 : 735-43.
9. Cho SN, Yanagihara DL, Hunter SW, Gelber RH, Brennan PJ. Serological specificity of phenolic glycolipid I from Mycobacterium leprae, and use in serodiagnosis of leprosy. Infect Immun 1983; 41 : 1077-83.
10. Dasananjali K. The effectiveness of Multidrug therapy (MDT) for leprosy. Commun Dis J 1989; 15 : 252-67.
11. Dissanayake S, Young DB, Khanolkar SR, Miller RA, Buchanan TM. Evaluation of the significance of antibodies to the phenolic glycolipid of M. Leprae in leprosy patients and their contacts. Proc of XII Int Lep Conf, New Delhi. II/40(A), 1984.
12. FujiwaraT, Izumi S. Synthesis of the neoglycoconjugates of phenolic glycolipid-related trisaccharides for the serodiagnosis of leprosy. Agric Biol Chem 1987; 51 : 2539.
13. Fujiwara T, Hunter SW, Cho SN, Aspional GO, Brennan PJ. Chemical synthesis and serology of disaccharide and trisaccharide of phenolic glycolipid antigen from leprosy bacillus and preparation of a disaccharide protein conjagate for serodiagnosis of leprosy. Infect Immun 1984; 43 : 245-9.
14. Gonzalez-Abreau E, Gonzalez A. Seronegativity against the Mycobacterium Ieprae phenolic glycolipid I in mycobacterium infected or stimulated groups of individuals. Lepr Rev 1987; 58 : 149-54.
15. Grugni A, Nadkarni NJ, Kini MS, Mehta VR. Relapses in paucibacillary leprosy after MDT a clinical study. Int J Lepr 1990; 58 : 19-24.
16. Hunter SW, Fujiwara T, Brennan PJ. Structure and antigenicity of the major specific glycolipid antigen of Mycobacterium leprae. J Biol Chem 1982; 257 : 15072.
17. Izumi S, et al. Novel gelatin particle agglutination reaction for detecting M. leprae-specific antibodies in blood. Acta Dermatologica Kyoto 1988; 83 : 141-6.
18. Katoch K, et al. Results of a modified WHO regimen in highly bacilliferous BL/LL patients. Int J Lepr 1989; 57 : 451-7.
19. Kurz XM, Declercq EE Vellut CM. Rate and time distribution of relapses in multibacillary leprosy. Int J lepr 1989; 57: 599-606.
20. Li HY. Problems of leprosy relapse in China. Int J Lepr 1993; 63.1 : 1-7.
21. Lyons NF, Shannon EJ, Ellis BPB, Naafs B. Association of IgG, and IgM antibodies to phenolic glycolipid-1 antigen of Mycobacterium leprae with disease parameters in multibacillary leprosy patients. Lepr Rev 1988, 59 : 45-52.
22. Marchoux Chemotherapy Study Group. Relapses in multibacillary leprosy patients after stopping treatment with rifampicin-containing combined regimens. Int J Lepr 1992; 60: 525-35.
23. Noordeen SK. Leprosy control through multidrug therapy (MDT). Bull WHO 1991; 69 : 263-9.
24. Reddy PK, Mohinuddin SK. Pattern of relapses in paucibacillary leprosy patients treated with MDT (WHO 1982). Indian J Lepr 1988; 60 : 581-8.
25. Ridley DS, Jopling WH. Classification of leprosy according to immunity; a five-group system. Int J Lepr 1966; 34 : 253-73.
26. Sugiyama K, Matsumoto Y, Fujiwara T. Detection of M. leprae specific antibody by gelatin particle agglutination test. Acta Dermatologica Kyoto. 1988; 83 : 147-9.
27. Van Brakel W, Kist P, Noble S, O'Toole L. Relapses after multidrug therapy for leprosy: a preliminary report of 22 cases in West Nepal. Lepr Rev 1989; 60 : 45-50.
28. Young DB, Dissanayake S, Miller RA, Khanolkar SR, Buchanan TM. Humans respond predominantly with IgM Immunoglobulin fo the species-specific glycolipid of Mycobacterium leprae. J Infect Dis 1984; 149 : 870-3.